A Phase 2 interventional study of axitinib in Lung Neoplasms and Carcinoma, Non-small Cell Lung, sponsored by Pfizer. Completed at 11 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-06-26.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer — 15 open to participants now, 26 under way, 5 of them phase 3. Carcinoma, Non-Small-Cell Lung · Pfizer.
Among the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer, this one is the 102nd largest by enrollment of the 136 interventional ones that give a count, is one of 8 that started in 2005, is one of 45 in phase 2, and was the 12th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →15 of the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 18+
Pfizer · Sites in United States, Australia, China and 8 more countries
Ages 18+
Pfizer · Sites in United States, China, France and 6 more countries
Ages 18+
Pfizer · Sites in United States, Argentina, Australia and 17 more countries
Ages 18+
Pfizer · Sites in United States, Argentina, Australia and 26 more countries
Ages 18+
By country, each count listing its studies:
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
158 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 69 · Phase 2 58 · Phase 3 18 · Phase 4 4
First in 1999; this study’s year is marked. 8 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 32 is below the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 79 across the 136 interventional studies, 97 across the 17 observational. Of the 123 that completed or were terminated, 70 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
4 of the studies in Carcinoma, Non-Small-Cell Lung by Pfizer that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07567352PfizerA Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment | 2027-03-01 |
| NCT04389632Seagen, a wholly owned subsidiary of PfizerA Study of Sigvotatug Vedotin in Advanced Solid Tumors | 2027-06-16 |
| NCT05538130PfizerA Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors | 2027-08-31 |
| NCT05355701PfizerA Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. | 2027-08-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2 study being conducted at multiple centers in the United States and Germany. Patients having non-small cell lung cancer that has spread to other parts of the body (i.e., metastatic) or is locally advanced (i.e., Stage IIIB with malignant pleural effusion) are eligible to participate. Patients must have disease that has been treated with at least 1 prior treatment for metastatic disease (prior adjuvant treatment for localized disease does not count as prior treatment for metastatic disease). The purpose of the study is to test whether the angiogenesis inhibitor AG-013736 is an effective treatment for advanced non-small cell lung cancer as shown by the number of patients in the study who experience significant and durable tumor shrinkage
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
This study's enrollment of 32 is below the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Browse Carcinoma, Non-Small-Cell Lung studies →Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Compared within Carcinoma, Non-Small-Cell Lung, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lung Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AG-013736 is a vascular endothelial growth factor \[VEGF\] inhibitor
Drug: axitinib
Axitinib (AG-013736) tablet administered orally at a dose of 5 milligrams (mg) twice daily (BID) in cycles of 4 weeks.
Percentage of Participants With Objective Response (OR)
Percentage of participants with OR based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. CR are defined as the disappearance of all lesions (target and/or non target). PR are those with at least 30 percent (%) decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.
Time frame: Baseline until the date of first documented progression or discontinuation from the study due to any cause, assessed every 8 weeks up to 98 weeks
Progression-Free Survival (PFS)
Time in days from start of study treatment to first documentation of objective tumor progression or death due to any cause. PFS was calculated as first event date minus the date of first dose of study medication plus 1. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was "Death").
Time frame: Baseline until the date of first documented progression or death due to any cause, assessed every 8 weeks up to 98 weeks
Duration of Response (DR)
Time in days from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1. DR was calculated for the subgroup of participants with a confirmed objective tumor response.
Time frame: Baseline until the date of first documented progression or discontinuation from the study due to any cause, assessed every 8 weeks up to 98 weeks
Overall Survival (OS)
Time in days from the start of study treatment to date of death due to any cause. OS was calculated as the death date minus the date of first dose of study medication plus 1. Death was determined from AE data (where outcome was death) or from follow-up contact data (where the participant current status was death). For participants who were alive, overall survival was censored at the last contact.
Time frame: Baseline to death due to any cause or at least 1 year after the initial dose for the last treated participant
Population Pharmacokinetics for Axitinib (AG-013736) Plasma Concentrations
Population pharmacokinetic analysis involved mixed effects modeling using nonlinear mixed effects modeling (NONMEM) software. The intent of this analysis was to establish a basic population pharmacokinetic model for axitinib (AG-013736) and to determine inter-individual and residual variability in population (oral) clearance, and volume of distribution of drug. Relationship of demographic variables (gender, age, body weight, height and ethnicity), concomitant medications and measures of altered hepatic and renal function were examined by fitting measured axitinib (AG-013736) concentrations.
Time frame: Day 1 (pre-dose), Day 29, Day 57 and then every 8 weeks up to 98 weeks
Plasma Concentrations of Soluble Proteins
Plasma concentrations of soluble proteins (vascular endothelial growth factor \[VEGF\], placental growth factor \[PlGF\] and soluble vascular endothelial growth factor receptor-2 \[sVEGFR2\]) may be associated with tumor angiogenesis or tumor physiology and may correlate with efficacy or biological activity. It is presented as ratio to baseline, which is obtained by dividing the plasma soluble protein concentration at each time point by its concentration at baseline.
Time frame: Day 1 (pre-dose) and then every 8 weeks up to 98 weeks
| Milestone | Axitinib |
|---|---|
| Started | 32 |
| Completed | 0 |
| Not completed | 32 |
| Withdrew: Death | 2 |
| Withdrew: Lack of efficacy | 23 |
| Withdrew: Adverse event | 7 |
Percentage of participants with OR based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. CR are defined as the disappearance of all lesions (target and/or non target). PR are those with at least 30 percent (%) decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.
| Percentage of participants | Axitinib |
|---|---|
| Percentage of Participants With Objective Response (OR) | 9.4 (2.0 to 25.0) |
Time in days from start of study treatment to first documentation of objective tumor progression or death due to any cause. PFS was calculated as first event date minus the date of first dose of study medication plus 1. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was "Death").
| Days | Axitinib |
|---|---|
| Progression-Free Survival (PFS) | 148 (109 to 213) |
Time in days from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1. DR was calculated for the subgroup of participants with a confirmed objective tumor response.
| Days | Axitinib |
|---|---|
| Duration of Response (DR) | 252 (179 to 322) |
Time in days from the start of study treatment to date of death due to any cause. OS was calculated as the death date minus the date of first dose of study medication plus 1. Death was determined from AE data (where outcome was death) or from follow-up contact data (where the participant current status was death). For participants who were alive, overall survival was censored at the last contact.
| Days | Axitinib |
|---|---|
| Overall Survival (OS) | 450 (326 to NA) |
Population pharmacokinetic analysis involved mixed effects modeling using nonlinear mixed effects modeling (NONMEM) software. The intent of this analysis was to establish a basic population pharmacokinetic model for axitinib (AG-013736) and to determine inter-individual and residual variability in population (oral) clearance, and volume of distribution of drug. Relationship of demographic variables (gender, age, body weight, height and ethnicity), concomitant medications and measures of altered hepatic and renal function were examined by fitting measured axitinib (AG-013736) concentrations.
No measurements were reported for this outcome.
Plasma concentrations of soluble proteins (vascular endothelial growth factor \[VEGF\], placental growth factor \[PlGF\] and soluble vascular endothelial growth factor receptor-2 \[sVEGFR2\]) may be associated with tumor angiogenesis or tumor physiology and may correlate with efficacy or biological activity. It is presented as ratio to baseline, which is obtained by dividing the plasma soluble protein concentration at each time point by its concentration at baseline.
No measurements were reported for this outcome.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Axitinib | — | 16/32 (50%) | 31/32 (96.9%) |
| Event | Axitinib |
|---|---|
| Disease progression NOSGeneral disorders | 5/32 |
| ConfusionPsychiatric disorders | 3/32 |
| DehydrationMetabolism and nutrition disorders | 2/32 |
| Dyspnoea NOSRespiratory, thoracic and mediastinal disorders | 2/32 |
| Acute coronary syndromeCardiac disorders | 1/32 |
| Bradycardia, not otherwise specified (NOS)Cardiac disorders | 1/32 |
| AppendicitisGastrointestinal disorders | 1/32 |
| Colitis NOSGastrointestinal disorders | 1/32 |
| Diarrhoea haemorrhagicGastrointestinal disorders | 1/32 |
| DysphagiaGastrointestinal disorders | 1/32 |
| Event | Axitinib |
|---|---|
| FatigueGeneral disorders | 27/32 |
| Degreased appetiteMetabolism and nutrition disorders | 19/32 |
| DiarrhoeaGastrointestinal disorders | 15/32 |
| NauseaGastrointestinal disorders | 15/32 |
| DysphoniaRespiratory, thoracic and mediastinal disorders | 12/32 |
| Weight decreasedInvestigations | 11/32 |
| CoughRespiratory, thoracic and mediastinal disorders | 11/32 |
| VomitingGastrointestinal disorders | 10/32 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 10/32 |
| HypertensionVascular disorders | 10/32 |
| Age Continuous(Years) | Axitinib |
|---|---|
| Mean | 64.1 ± 12.3 |
| Sex: Female, Male(Participants) | Axitinib |
|---|---|
| Female | 13 |
| Male | 19 |
The record gives a start of Feb 2005, a primary completion of Jul 2007 and a completion of Jul 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2012, 4 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Axitinib
Carcinoma, Non-Small-Cell Lung →